US-based medical device company St. Jude Medical has secured the CE mark approval for its SyncAV CRT software adding to the company’s cardiac resynchronisation therapy (CRT) portfolio.
The SyncAV CRT software algorithm, which is based on the company’s MultiPoint Pacing technology, is designed to treat heart failure patients who had a failed response to other pacing options.
The SyncAV technology automatically adjusts pacing based on real-time changes in a patient’s cardiac condition.
It provides an opportunity to the physicians to further improve treatment of patients who have responded positively to traditional CRT.
John Radcliffe Hospital Oxford Heart Centre consultant cardiologist and electrophysiologist Dr Timothy Betts said: "Although we have made substantial improvements in how we treat heart failure patients, there are still certain patients who are not getting the outcomes with traditional CRT that we would like to see.
"The SyncAV CRT algorithm dynamically individualises programming to work towards providing patients with the right settings at the right time helping offer the best possible outcome for even our most complex patients.
"Our goal is to utilise the technology to improve outcomes while offering patients who do not respond to therapy with additional options for treatment."
The CRT technology resynchronises the lower chambers (ventricles) of the heart by issuing uniquely programmed electrical impulses to stimulate each ventricle to beat in sync to offer the best cardiac performance.
The company has also secured the CE mark approval for its Quadra Assura MP CRT-Defibrillator (CRT-D) with full-body magnetic resonance (MR) labeling which allows the patients an unrestricted access to MRI diagnostic testing.
Image: Quadra Assura MP CRT-D. Photo: courtesy of St. Jude Medical.
